Literature DB >> 14582923

Chronic obstructive pulmonary disease: molecular and cellular mechanisms.

P J Barnes1, S D Shapiro, R A Pauwels.   

Abstract

Chronic obstructive pulmonary disease is a leading cause of death and disability, but has only recently been extensively explored from a cellular and molecular perspective. There is a chronic inflammation that leads to fixed narrowing of small airways and alveolar wall destruction (emphysema). This is characterised by increased numbers of alveolar macrophages, neutrophils and cytotoxic T-lymphocytes, and the release of multiple inflammatory mediators (lipids, chemokines, cytokines, growth factors). A high level of oxidative stress may amplify this inflammation. There is also increased elastolysis and evidence for involvement of several elastolytic enzymes, including serine proteases, cathepsins and matrix metalloproteinases. The inflammation and proteolysis in chronic obstructive pulmonary disease is an amplification of the normal inflammatory response to cigarette smoke. This inflammation, in marked contrast to asthma, appears to be resistant to corticosteroids, prompting a search for novel anti-inflammatory therapies that may prevent the relentless progression of the disease.

Entities:  

Mesh:

Year:  2003        PMID: 14582923     DOI: 10.1183/09031936.03.00040703

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  415 in total

Review 1.  Pathophysiology of bronchoconstriction: role of oxidatively damaged DNA repair.

Authors:  Attila Bacsi; Lang Pan; Xueqing Ba; Istvan Boldogh
Journal:  Curr Opin Allergy Clin Immunol       Date:  2016-02

2.  Klotho Reduction in Alveolar Macrophages Contributes to Cigarette Smoke Extract-induced Inflammation in Chronic Obstructive Pulmonary Disease.

Authors:  Lingling Li; Yujie Wang; Wei Gao; Cheng Yuan; Sini Zhang; Hong Zhou; Mao Huang; Xin Yao
Journal:  J Biol Chem       Date:  2015-09-18       Impact factor: 5.157

Review 3.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Effects of VLA-1 Blockade on Experimental Inflammation in Mice.

Authors:  Ryuichi Totsuka; Takaaki Kondo; Shigeki Matsubara; Midori Hirai; Yoichi Kurebayashi
Journal:  Kobe J Med Sci       Date:  2016-07-05

5.  Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.

Authors:  Yosuke Yamada; Utano Tomaru; Akihiro Ishizu; Tomoki Ito; Takayuki Kiuchi; Ayako Ono; Syota Miyajima; Katsura Nagai; Tsunehito Higashi; Yoshihiro Matsuno; Hirotoshi Dosaka-Akita; Masaharu Nishimura; Soichi Miwa; Masanori Kasahara
Journal:  Lab Invest       Date:  2015-04-27       Impact factor: 5.662

6.  Induction of CYP1A1, CYP1A2, CYP1B1, increased oxidative stress and inflammation in the lung and liver tissues of rats exposed to incense smoke.

Authors:  Tajamul Hussain; Omar S Al-Attas; Nasser M Al-Daghri; Arif A Mohammed; Edgard De Rosas; Shebl Ibrahim; Benjamin Vinodson; Mohammed G Ansari; Khaled I Alam El-Din
Journal:  Mol Cell Biochem       Date:  2014-02-21       Impact factor: 3.396

7.  Myeloid-specific Fos-related antigen-1 regulates cigarette smoke-induced lung inflammation, not emphysema, in mice.

Authors:  Michelle Vaz; Subbiah Rajasekaran; Haranatha R Potteti; Sekhar P Reddy
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

8.  Mitochondrial localization and function of heme oxygenase-1 in cigarette smoke-induced cell death.

Authors:  Dirk-Jan Slebos; Stefan W Ryter; Marco van der Toorn; Fang Liu; Fengli Guo; Catherine J Baty; Jenny M Karlsson; Simon C Watkins; Hong Pyo Kim; Xue Wang; Janet S Lee; Dirkje S Postma; Henk F Kauffman; Augustine M K Choi
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

Review 9.  Autophagy in Pulmonary Diseases.

Authors:  Kiichi Nakahira; Maria Angelica Pabon Porras; Augustine M K Choi
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

Review 10.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.